Cue Biopharma Inc (NASDAQ:CUE) Q2 2025 Earnings: Revenue Surpasses Estimates, Loss Narrower Than Expected

Cue Biopharma Inc (NASDAQ:CUE) Reports Q2 2025 Earnings: Revenue Beats Estimates, Narrower-Than-Expected Loss

Cue Biopharma Inc released its second-quarter 2025 financial results, posting revenue and earnings per share (EPS) figures that surpassed analyst expectations. The clinical-stage biopharmaceutical company reported revenue of $2.95 million, exceeding the consensus estimate of $2.42 million. Meanwhile, the company’s net loss per share came in at -$0.09, better than the anticipated -$0.14.

Key Financial Highlights:

• Revenue: $2.95M (vs. $2.42M estimated) – a 22% beat.
• EPS: -$0.09 (vs. -$0.14 estimated) – a narrower loss than projected.
• Full-Year Estimates: Analysts expect full-year 2025 revenue of $8.16M and an EPS of -$0.60.
• Q3 2025 Estimates: Revenue is projected at $2.78M with an EPS of -$0.13.

The market reaction has been cautiously positive, with shares rising approximately 2% in after-hours trading. Over the past month, the stock has gained nearly 13%, though it remains slightly down over the past week (-5.7%).

Business and Clinical Updates
The company highlighted progress in its Immuno-STAT platform, which focuses on modulating disease-specific T cells for autoimmune diseases and cancer. Notably, Cue Biopharma received FDA feedback on its Pre-IND Briefing Document for CUE-401, reinforcing plans to advance the investigational new drug (IND) submission. This candidate targets autoimmune conditions by enhancing regulatory T cells (Tregs).

While the press release did not provide a formal financial outlook, the company’s clinical advancements and stronger-than-expected earnings suggest continued momentum in its pipeline development.

Market Implications
The revenue beat and improved EPS performance indicate that Cue Biopharma is executing effectively despite its clinical-stage status. The after-hours uptick suggests investor optimism, though the stock’s recent volatility reflects the inherent risks of biotech investing, particularly for companies yet to commercialize a product.

For a deeper dive into Cue Biopharma’s earnings and analyst estimates, visit the earnings page.

Disclaimer: This article is for informational purposes only and does not constitute investment advice. Investors should conduct their own research or consult a financial advisor before making any decisions.